DOV Initiates Second Bicifadine Phase III Trial In Revamped Population
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
DOV Pharmaceuticals' second Phase III clinical trial for its chronic lower back pain agent bicifadine will enroll a limited patient population, the company announced May 22
You may also be interested in...
DOV Confident Of Bicifadine "Residual Value" For Pain After Phase III Failure
DOV's analysis of a failed Phase III trial of its non-opioid analgesic bicifadine for chronic low back pain could be used to modify future and ongoing studies for the indication, according to the company
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product